ArticleDiscover oncology2025
Prognostic and immunological characterization of osteosarcoma patients evaluated by liquid-liquid phase separation related genes.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification and validation of the potential therapeutic value of CASK in osteosarcoma: a computational analysis andFrontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundLiquid-liquid phase separation has been reported to be closely related to the development and occurrence of tumors, but its role in osteosarcoma remains unexplored.
methodsFor the first time, based on liquid-liquid phase separation related genes (LLPSRGs), a prognostic model was constructed through multivariate Cox regression. The model was validated on an independent dataset. The patients were grouped based on the median risk score. Simultaneously conduct immune infiltration analysis, enrichment analysis and drug sensitivity evaluation.
resultsWe have identified for the first time 3 LLPSRGs associated with osteosarcoma prognosis. A prognostic model was constructed based on LLPSRGs and validated in an independent dataset. The signature is an independent risk factor for osteosarcoma patients, the signature was associated with the tumor microenvironment.
conclusionswe conducted a comprehensive analysis of LLPSRGs in osteosarcoma patients for the first time and identified 3 LLPSRGs that may be associated with the prognosis of osteosarcoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.